Literature DB >> 16550545

Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.

Anna Brück1, Sargo Aalto, Elina Nurmi, Tero Vahlberg, Jörgen Bergman, Juha O Rinne.   

Abstract

Thirty-one drug-naive patients with Parkinson's disease (PD) underwent 6-[18F]fluoro-L-dopa (F-dopa) positron emission tomography (PET) scan at the time of the diagnosis (baseline) and 2 years later in order to investigate F-dopa uptake in striatal and extrastriatal regions during the first years of early PD. Twenty-four healthy controls underwent one F-dopa PET scan. The regional differences in the striatal and extrastriatal regions were analyzed with statistical parametric mapping and automated region of interest analyses. Our study shows that the F-dopa uptake in unmedicated early PD is most severely decreased in the dorsal part of caudal putamen but significant decrease can be seen throughout the striatum compared with controls. During the first years of PD, there is a progressive regional decline in striatal F-dopa uptake, the dorsal part of caudal putamen being still the most severely affected region. The absolute decline is equal between the striatal subregions. This suggests that the decline of dopamine function starts from the dorsocaudal putamen, but once started, the rate of progression is equal between the subregions of the striatum. In contrast to the striatal decline, the increased cortical F-dopa uptake prevails at least during the first years of PD. (c) 2006 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16550545     DOI: 10.1002/mds.20855

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  33 in total

1.  A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.

Authors:  Catherine L Gallagher; Bradley T Christian; James E Holden; Onofre T Dejesus; Robert J Nickles; Laura Buyan-Dent; Barbara B Bendlin; Sandra J Harding; Charles K Stone; Barb Mueller; Sterling C Johnson
Journal:  Mov Disord       Date:  2011-06-02       Impact factor: 10.338

Review 2.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

Review 3.  Rule-based category learning in patients with Parkinson's disease.

Authors:  Amanda Price; J Vincent Filoteo; W Todd Maddox
Journal:  Neuropsychologia       Date:  2009-02-02       Impact factor: 3.139

4.  Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease.

Authors:  Ruth Djaldetti; Therese A Treves; Ilan Ziv; Eldad Melamed; Yair Lampl; Mordechai Lorberboym
Journal:  Neurol Sci       Date:  2009-06-05       Impact factor: 3.307

Review 5.  Neuroimaging and transcranial ultrasonography in Parkinson's disease.

Authors:  Shyamal H Mehta; John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

Review 6.  PET/CT in diagnosis of movement disorders.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

7.  Dopaminergic basis for impairments in functional connectivity across subdivisions of the striatum in Parkinson's disease.

Authors:  Peter T Bell; Moran Gilat; Claire O'Callaghan; David A Copland; Michael J Frank; Simon J G Lewis; James M Shine
Journal:  Hum Brain Mapp       Date:  2014-11-25       Impact factor: 5.038

8.  Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.

Authors:  Agnese Picco; Silvia Morbelli; Arnoldo Piccardo; Dario Arnaldi; Nicola Girtler; Andrea Brugnolo; Irene Bossert; Lucio Marinelli; Antonio Castaldi; Fabrizio De Carli; Claudio Campus; Giovanni Abbruzzese; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-28       Impact factor: 9.236

9.  Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Hiroto Kuwabara; Gregory M Constantine; Chester A Mathis; Robert Y Moore
Journal:  Neurosci Lett       Date:  2007-08-06       Impact factor: 3.046

10.  Brain activity during complex imagined gait tasks in Parkinson disease.

Authors:  Daniel S Peterson; Kristen A Pickett; Ryan P Duncan; Joel S Perlmutter; Gammon M Earhart
Journal:  Clin Neurophysiol       Date:  2013-11-05       Impact factor: 3.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.